KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00076568" target="_blank" >RIV/00216224:14110/14:00076568 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/62156489:43210/14:00230469 RIV/62157124:16370/14:43872689
Výsledek na webu
<a href="http://dx.doi.org/10.1039/c4mt00065j" target="_blank" >http://dx.doi.org/10.1039/c4mt00065j</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1039/c4mt00065j" target="_blank" >10.1039/c4mt00065j</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer
Popis výsledku v původním jazyce
Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, theexpression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1 alpha, KRAS, mTOR, MT1A, MT2A, NF-kappa B1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher.
Název v anglickém jazyce
KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer
Popis výsledku anglicky
Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, theexpression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1 alpha, KRAS, mTOR, MT1A, MT2A, NF-kappa B1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
CE - Biochemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Metallomics
ISSN
1756-5901
e-ISSN
—
Svazek periodika
6
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
14
Strana od-do
1240-1253
Kód UT WoS článku
000338638000009
EID výsledku v databázi Scopus
—